Recently, Linzer et al. [48] have also showed that increased DES1 levels, found in a subset of HER2+ tumors, were associated with the more aggressive and metastatic phenotype of this BC subtype and with worse survival outcomes of the patients (Table 1). This evidence concerns the gene ERBB2 and breast cancer.